Melflufen—A Novel Agent in the Treatment of Relapsed/Refractory Multiple Myeloma

Support: No funding was received in the publication of this article. Multiple myeloma (MM) is the second most common hematological malignancy after non-Hodgkin’s lymphoma. Although recent decades have seen considerable advances and improvements in clinical outcomes for patients with MM, MM remains incurable, with a high disease burden. Clonal evolution and genomic instability within myeloma clones inevitably lead to disease progression and treatment resistance. An increasing number of patients are becoming refractory to multiple treatments; therefore, there is a need for new drugs with novel mechanisms of action.